RMD:NYSEResMed Inc. Analysis

ResMed (RMD) is trading around $208.98, just above its 20‑day SMA of $208.52 but below the 50‑day SMA of $219.32, with a clear support level at $198.61 and resistance near $223.92. The RSI sits at 45, indicating neutral momentum, while the MACD histogram is positive ($1.20) and the signal line has turned bullish, suggesting a potential short‑term bounce despite a broader bearish trend and decreasing volume. On the fundamentals side, the company posted an 11% revenue increase to $5.54 bn, maintained a strong gross margin of 62% and operating margin of 35%, and delivered a non‑GAAP EPS of $10.32 with forward EPS projected at $12.20. Cash generation remains robust with $1.89 bn operating cash flow and a low debt‑to‑equity of 13, supporting a sustainable dividend yield of 1.14% and a modest payout ratio of 22%.
Valuation metrics show a current price slightly below the DCF‑derived fair value of $210 and well under the industry PE average of 27.3, delivering an estimated upside of nearly 30% to the median analyst target of $286. The stock’s low beta (≈0.62) and moderate volatility (≈26% 30‑day) temper market risk, while the healthcare‑device sector presents limited regulatory turbulence. Overall, the blend of solid earnings growth, attractive valuation, and dividend sustainability positions RMD as a compelling buy for medium‑ to long‑term investors.